CORRECTION article

Front. Cell Dev. Biol., 28 August 2025

Sec. Cancer Cell Biology

Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1672461

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway

  • 1. Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China

  • 2. Adult Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom

  • 3. The Institute of Cancer Research, London, United Kingdom

  • 4. Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

  • 5. Center of Scientific Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China

  • 6. Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States

  • 7. 3B’s Research Group, I3Bs – Research Institute on Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, University of Minho, Guimarães, Portugal

  • 8. ICVS/3B’s – PT Government Associate Laboratory, Guimarães, Portugal

There was a mistake in Figures 2, 4 as published. The wrong images were erroneously used for Figures 2G, 4A. The corrected Figures 2, 4 appear below.

FIGURE 2

FIGURE 4

The original version of this article has been updated.

Statements

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

gastric cancer, L-OHP resistance, homologous recombination, PARP1 inhibitors, organoid

Citation

Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y and Zhang C (2025) Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. Front. Cell Dev. Biol. 13:1672461. doi: 10.3389/fcell.2025.1672461

Received

24 July 2025

Accepted

08 August 2025

Published

28 August 2025

Volume

13 - 2025

Edited and reviewed by

Ira Ida Skvortsova, Innsbruck Medical University, Austria

Updates

Copyright

*Correspondence: Changhua Zhang, ; Yulong He, ; Axel Behrens,

† These authors share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics